Shintaro Tsuruoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shintaro Tsuruoka has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Hirofumi Ishikawa
Department of Radiology Ehime University Graduate School of Medicine Toon Japan
2 shared publications- Kenji Makita
Department of Radiation Oncology, National Cancer Center Japan Hospital East, Kashiwa, Japan
2 shared publications Kotaro Uwatsu
Department of Radiology Ehime University Graduate School of Medicine Toon Japan
2 shared publications- Noriko Takata
Department of Radiology, Ehime University Hospital, Toon, Japan
2 shared publications - Teruhito Kido
Department of Radiology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan
2 shared publications - Hiromitsu Kanzaki
Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Kou-160, Minami-Umenomoto-Machi, Matsuyama 791-0280, Ehime, Japan
1 shared publication
Latest Publications
- Open Access
- 3 February 2023
- Published by MDPI AG in Medical Sciences
- Vol. 11 (1) , 17
Factors Affecting Survival and Local Control in Patients with Bone Metastases Treated with Radiotherapy
The aim of this study was to evaluate the expected prognosis and factors affecting local control (LC) of the bone metastatic sites treated with palliative external beam radiotherapy (RT). Between December 2010 and April 2019, 420 cases (male/female = 240/180; median age [range]: 66 [12–90] years) with predominantly osteolytic bone metastases received RT and were evaluated. LC was evaluated by follow-up computed tomography (CT) image. Median RT doses (BED10) were 39.0 Gy (range, 14.4–71.7 Gy). The 0.5-year overall survival and LC of RT sites were 71% and 84%, respectively. Local recurrence on CT images was observed in 19% (n = 80) of the RT sites, and the median recurrence time was 3.5 months (range, 1–106 months). In univariate analysis, abnormal laboratory data before RT (platelet count, serum albumin, total bilirubin, lactate dehydrogenase, or serum calcium level), high-risk primary tumor sites (colorectal, esophageal, hepatobiliary/pancreatic, renal/ureter, and non-epithelial cancers), no antineoplastic agents (ATs) administration after RT, and no bone modifying agents (BMAs) administration after RT were significantly unfavorable factors for both survival and LC of RT sites. Sex (male), performance status (≥3), and RT dose (BED10) (10) (<39.0 Gy), and sex (male) were significantly unfavorable factors for survival, and primary tumor sites and BMAs administration after RT were significantly unfavorable factors for LC of RT sites. In conclusion, laboratory data before RT was important factor both prognosis and LC of bone metastases treated with palliative RT. At least in patients with abnormal laboratory data before RT, palliative RT seemed to be focused on the only pain relief.
- 3 February 2023
- Published by MDPI AG in Medical Sciences
- Vol. 11 (1) , 17
Open AccessFactors Affecting Survival and Local Control in Patients with Bone Metastases Treated with Radiotherapy
The aim of this study was to evaluate the expected prognosis and factors affecting local control (LC) of the bone metastatic sites treated with palliative external beam radiotherapy (RT). Between December 2010 and April 2019, 420 cases (male/female = 240/180; median age [range]: 66 [12–90] years) with predominantly osteolytic bone metastases received RT and were evaluated. LC was evaluated by follow-up computed tomography (CT) image. Median RT doses (BED10) were 39.0 Gy (range, 14.4–71.7 Gy). The 0.5-year overall survival and LC of RT sites were 71% and 84%, respectively. Local recurrence on CT images was observed in 19% (n = 80) of the RT sites, and the median recurrence time was 3.5 months (range, 1–106 months). In univariate analysis, abnormal laboratory data before RT (platelet count, serum albumin, total bilirubin, lactate dehydrogenase, or serum calcium level), high-risk primary tumor sites (colorectal, esophageal, hepatobiliary/pancreatic, renal/ureter, and non-epithelial cancers), no antineoplastic agents (ATs) administration after RT, and no bone modifying agents (BMAs) administration after RT were significantly unfavorable factors for both survival and LC of RT sites. Sex (male), performance status (≥3), and RT dose (BED10) (10) (<39.0 Gy), and sex (male) were significantly unfavorable factors for survival, and primary tumor sites and BMAs administration after RT were significantly unfavorable factors for LC of RT sites. In conclusion, laboratory data before RT was important factor both prognosis and LC of bone metastases treated with palliative RT. At least in patients with abnormal laboratory data before RT, palliative RT seemed to be focused on the only pain relief.
- 25 October 2022
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (3) , 347-354
Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy
Purpose: To evaluate the prognostic value of human epidermal growth factor receptor 2 (HER2) status and how to use HER2‐targeted therapy in breast cancer (BC) with brain metastases (BM) treated with radiotherapy.Methods: We retrospectively reviewed the data of 103 BC patients with parenchymal BM treated with radiotherapy. We collected data on the hormone receptor (HR), HER‐2 amplification status, and systemic therapy after treatment for BM. The primary outcome was overall survival (OS), which was calculated from the diagnosis of BM to death.Results: The median follow‐up time from the diagnosis of the first BM was 9.1 months (range, .7–88 months). The 2‐year OS of the HR‐positive and HER2‐positive (HR+HER2+) BC (31.3 mo) was significantly better than those of the HR‐HER2+ (9,5 mo, p=.002), HR+HER2‐ (9.9mo, p=.003), and triple‐negative BC (3.9 mo, p<.001) ( . Of the 36 HER2‐positive patients, 31 patients treated with HER2‐targeted therapy after radiotherapy for BM had a significantly better 2‐year OS than those who did not receive HER2‐targeted therapy (43% vs. 0%; p < .001). Among the 31 patients treated with HER2‐targeted therapy, the 2‐year OS for those treated with multiple anti‐HER2 agents during the entire course of treatment was significantly higher than that for patients treated with a single agent (60% vs. 24%; p = .006).Conclusions: HR+HER2+ BC patients with BM treated with radiotherapy show a better prognosis than other subtypes. For HER2‐positive patients with good prognosis, it may be important to continue HER2‐targeted therapy appropriately after radiotherapy for BM.
- 25 October 2022
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (3) , 347-354
Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy
Purpose: To evaluate the prognostic value of human epidermal growth factor receptor 2 (HER2) status and how to use HER2‐targeted therapy in breast cancer (BC) with brain metastases (BM) treated with radiotherapy.Methods: We retrospectively reviewed the data of 103 BC patients with parenchymal BM treated with radiotherapy. We collected data on the hormone receptor (HR), HER‐2 amplification status, and systemic therapy after treatment for BM. The primary outcome was overall survival (OS), which was calculated from the diagnosis of BM to death.Results: The median follow‐up time from the diagnosis of the first BM was 9.1 months (range, .7–88 months). The 2‐year OS of the HR‐positive and HER2‐positive (HR+HER2+) BC (31.3 mo) was significantly better than those of the HR‐HER2+ (9,5 mo, p=.002), HR+HER2‐ (9.9mo, p=.003), and triple‐negative BC (3.9 mo, p<.001) ( . Of the 36 HER2‐positive patients, 31 patients treated with HER2‐targeted therapy after radiotherapy for BM had a significantly better 2‐year OS than those who did not receive HER2‐targeted therapy (43% vs. 0%; p < .001). Among the 31 patients treated with HER2‐targeted therapy, the 2‐year OS for those treated with multiple anti‐HER2 agents during the entire course of treatment was significantly higher than that for patients treated with a single agent (60% vs. 24%; p = .006).Conclusions: HR+HER2+ BC patients with BM treated with radiotherapy show a better prognosis than other subtypes. For HER2‐positive patients with good prognosis, it may be important to continue HER2‐targeted therapy appropriately after radiotherapy for BM.
- 1 June 2021
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 35 (9) , 1015-1021
Usefulness of albumin–globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine
Objective Albumin–globulin ratio (AGR), which is calculated by dividing serum albumin by serum globulin, is considered as a cancer-related inflammation biomarker. Although the prognosis of many solid cancers has been shown to be associated with AGR, there are no studies to demonstrate the association between the prognosis of thyroid cancer and AGR. The purpose of this study is to reveal the relationship between AGR and overall survival (OS) in patients with thyroid cancer who received radioactive iodine therapy (RIT). Methods Eighty-eight patients with thyroid cancer who had received RIT for the first time in our institution were included. The values before RIT were adopted as initial measurements for serum albumin, globulin, and thyroglobulin (Tg) and used for analysis. Patients were divided into two groups based on the AGR value. We analyzed the relationship between clinical factors and treatment outcome. Results The median follow-up period was 92.4 months (range: 30.1–173.9 months). The 5-year OS and progression-free survival (PFS) were 94% and 54%, respectively. Seventeen patients (< 65 years, 8; and ≥ 65 years, 9) died during the follow-up period. Low AGR was significantly associated with OS in both univariate and multivariate analyses (p = 0.0059 and p = 0.0120, respectively). As the 5-year OS was as high as 94%, there was no significant difference in survival rate between the two groups during the first 5 years. However, there seemed to be a remarkable difference in 10 years after the first RIT. On the other hand, Tg was significantly associated with PFS in both univariate and multivariate analyses (p = 0.0016 and p = 0.0441, respectively). In patients under the age of 65, the PFS rate was significantly lower in the low AGR group (p < 0.0001), while there was no difference in PFS rate between the two AGR groups in patients aged 65 years or older. Conclusions AGR may be used as a prognostic factor in relatively younger patients with thyroid cancer treated with radioiodine, while it may be less useful in the older. Overall, it may be an independent prognostic factor for long-term survival in those with thyroid cancer.
- 1 June 2021
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 35 (9) , 1015-1021
Usefulness of albumin–globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine
Objective Albumin–globulin ratio (AGR), which is calculated by dividing serum albumin by serum globulin, is considered as a cancer-related inflammation biomarker. Although the prognosis of many solid cancers has been shown to be associated with AGR, there are no studies to demonstrate the association between the prognosis of thyroid cancer and AGR. The purpose of this study is to reveal the relationship between AGR and overall survival (OS) in patients with thyroid cancer who received radioactive iodine therapy (RIT). Methods Eighty-eight patients with thyroid cancer who had received RIT for the first time in our institution were included. The values before RIT were adopted as initial measurements for serum albumin, globulin, and thyroglobulin (Tg) and used for analysis. Patients were divided into two groups based on the AGR value. We analyzed the relationship between clinical factors and treatment outcome. Results The median follow-up period was 92.4 months (range: 30.1–173.9 months). The 5-year OS and progression-free survival (PFS) were 94% and 54%, respectively. Seventeen patients (< 65 years, 8; and ≥ 65 years, 9) died during the follow-up period. Low AGR was significantly associated with OS in both univariate and multivariate analyses (p = 0.0059 and p = 0.0120, respectively). As the 5-year OS was as high as 94%, there was no significant difference in survival rate between the two groups during the first 5 years. However, there seemed to be a remarkable difference in 10 years after the first RIT. On the other hand, Tg was significantly associated with PFS in both univariate and multivariate analyses (p = 0.0016 and p = 0.0441, respectively). In patients under the age of 65, the PFS rate was significantly lower in the low AGR group (p < 0.0001), while there was no difference in PFS rate between the two AGR groups in patients aged 65 years or older. Conclusions AGR may be used as a prognostic factor in relatively younger patients with thyroid cancer treated with radioiodine, while it may be less useful in the older. Overall, it may be an independent prognostic factor for long-term survival in those with thyroid cancer.